Last reviewed · How we verify
euglycemic hyperinsulinemic clamp
euglycemic hyperinsulinemic clamp is a Small molecule drug developed by Hospices Civils de Lyon. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | euglycemic hyperinsulinemic clamp |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion (NA)
- The Role of Endocannabinoids in Insulin Production and Action (PHASE1)
- Reprometabolic Syndrome Mediates Subfertility in Obesity (NA)
- Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance. (PHASE1)
- VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway (PHASE2)
- Hypoglycemia and Autonomic Nervous System Function-B (PHASE4)
- Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes (EARLY_PHASE1)
- Effect of Apelin on Insulin Sensitivity in Type 2 Diabetic Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- euglycemic hyperinsulinemic clamp CI brief — competitive landscape report
- euglycemic hyperinsulinemic clamp updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI
Frequently asked questions about euglycemic hyperinsulinemic clamp
What is euglycemic hyperinsulinemic clamp?
Who makes euglycemic hyperinsulinemic clamp?
What development phase is euglycemic hyperinsulinemic clamp in?
Related
- Manufacturer: Hospices Civils de Lyon — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing